CVnCoV – CureVac AG vs placebo
Confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
8 questions · 8 findings · 1 reviews
No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 2 · 25%Low 1 · 12.5%Moderate 2 · 25%High 2 · 25%
CVnCoV – CureVac AG vs placebo
Confirmed symptomatic COVID‐19b
1 finding from 1 review
- no estimate extracted1 study · 25062 participantsModerate
CVnCoV – CureVac AG vs placebo
Severe or critical COVID‐19
1 finding from 1 review
- no estimate extracted1 study · 25062 participantsVery low
CVnCoV – CureVac AG vs placebo
All‐cause mortalityh
It is very uncertain whether CVnCoV – CureVac AG changes all‐cause mortalityh compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.33 [0.46, 3.83]1 study · 39529 participantsVery low
CVnCoV – CureVac AG vs placebo
Systemic reactogenicity events
CVnCoV – CureVac AG leads to higher systemic reactogenicity eventsi compared with placebo (high certainty).
1 finding from 1 review
- RR 1.48 [1.43, 1.53]1 study · 3982 participantsHigh
CVnCoV – CureVac AG vs placebo
Any adverse eventj
CVnCoV – CureVac AG probably leads to higher any adverse eventj compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.42 [1.38, 1.47]1 study · 3982 participantsModerate
CVnCoV – CureVac AG vs placebo
Serious adverse eventsk
CVnCoV – CureVac AG showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
1 finding from 1 review
- RR 1.24 [0.9, 1.71]1 study · 39529 participantsLow
CVnCoV – CureVac AG vs placebo
Local reactogenicity events
CVnCoV – CureVac AG leads to higher local reactogenicity eventsi compared with placebo (high certainty).
1 finding from 1 review
- RR 3.51 [3.24, 3.81]1 study · 3982 participantsHigh